Elisabetta Menna

Dr. Elisabetta Menna

orcid

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2018 in Immunity
Verified
Journal Article
Closed access
FFFabia Filipello
Fabia Filipello
RMRaffaella Morini
Raffaella Morini
ICIrene Corradini
Irene Corradini
VZValerio Zerbi
Valerio Zerbi
ACAlice Canzi
Alice Canzi
MMMichela Matteoli
Michela Matteoli

19 March 2009 in The EMBO Journal
Verified
Journal Article
Open access
PDF file
FBFabio Bianco
Fabio Bianco
Cristiana PerrottaCristiana Perrotta
Cristiana Perrotta
LNLuisa Novellino
Luisa Novellino
MFMaura Francolini
Maura Francolini
LRLoredana Riganti
Loredana Riganti
CFChiara Fenoglio
Chiara Fenoglio
We have earlier shown that microglia, the immune cells of the CNS, release microparticles from cell plasma membrane after ATP stimulation. These vesicles contain and release IL‐1β, a crucial cytokine in CNS inflammatory events. In this study, we show that microparticles are also released by astrocytes and we get insights into the mechanism of their shedding. We show that, on activation of the ATP receptor P2X7, microparticle shedding is associated with rapid activation of acid sphingomyelinase, which moves to plasma membrane outer leaflet. ATP‐induced shedding and IL‐1β release are markedly reduced by the inhibition of acid sphingomyelinase, and completely blocked in glial cultures from acid sphingomyelinase knockout mice. We also show that p38 MAPK cascade is relevant for the whole process, as specific kinase inhibitors strongly reduce acid sphingomyelinase activation, microparticle shedding and IL‐1β release. Our results represent the first demonstration that activation of acid sphingomyelinase is necessary and sufficient for microparticle release from glial cells and define key molecular effectors of microparticle formation and IL‐1β release, thus, opening new strategies for the treatment of neuroinflammatory diseases.

24 March 2016 in Frontiers in Synaptic Neuroscience
Verified
Journal Article
Open access
FAFlavia Antonucci
Flavia Antonucci
ICIrene Corradini
Irene Corradini
GFGiuliana Fossati
Giuliana Fossati
RTRomana Tomasoni
Romana Tomasoni
EMElisabetta Menna
Elisabetta Menna
MMMichela Matteoli
Michela Matteoli
A hallmark of synaptic specializations is their dependence on highly organized complexes of proteins that interact with each other. The loss or modification of key synaptic proteins directly affects the properties of such networks, ultimately impacting synaptic function. SNAP-25 is a component of the SNARE complex, which is central to synaptic vesicle exocytosis, and, by directly interacting with different calcium channels subunits, it negatively modulates neuronal voltage-gated calcium channels, thus regulating intracellular calcium dynamics. The SNAP-25 gene has been associated with distinct brain diseases, including Attention Deficit Hyperactivity Disorder (ADHD), schizophrenia and bipolar disorder, indicating that the protein may act as a shared biological substrate among different “synaptopathies”. The mechanisms by which alterations in SNAP-25 may concur to these psychiatric diseases are still undefined, although alterations in neurotransmitter release have been indicated as potential causative processes. This review summarizes recent work showing that SNAP-25 not only controls exo/endocytic processes at the presynaptic terminal, but also regulates postsynaptic receptor trafficking, spine morphogenesis and plasticity, thus opening the possibility that SNAP-25 defects may contribute to psychiatric diseases by impacting not only presynaptic but also postsynaptic functions.

1 November 2021 in Immunity
Verified
Journal Article
Open access
FMFilippo Mirabella
Filippo Mirabella
GDGenni Desiato
Genni Desiato
SMSara Mancinelli
Sara Mancinelli
GFGiuliana Fossati
Giuliana Fossati
MRMarco Rasile
Marco Rasile
DPDavide Pozzi
Davide Pozzi
Early prenatal inflammatory conditions are thought to be a risk factor for different neurodevelopmental disorders. Maternal interleukin-6 (IL-6) elevation during pregnancy causes abnormal behavior in offspring, but whether these defects result from altered synaptic developmental trajectories remains unclear. Here we showed that transient IL-6 elevation via injection into pregnant mice or developing embryos enhanced glutamatergic synapses and led to overall brain hyperconnectivity in offspring into adulthood. IL-6 activated synaptogenesis gene programs in glutamatergic neurons and required the transcription factor STAT3 and expression of the RGS4 gene. The STAT3-RGS4 pathway was also activated in neonatal brains during poly(I:C)-induced maternal immune activation, which mimics viral infection during pregnancy. These findings indicate that IL-6 elevation at early developmental stages is sufficient to exert a long-lasting effect on glutamatergic synaptogenesis and brain connectivity, providing a mechanistic framework for the association between prenatal inflammatory events and brain neurodevelopmental disorders.

30 June 2009 in PLOS Biology
Verified
Journal Article
Open access
PDF file
EMElisabetta Menna
Elisabetta Menna
Andrea DisanzaAndrea Disanza
Andrea Disanza
CCCinzia Cagnoli
Cinzia Cagnoli
USUrsula Schenk
Ursula Schenk
GGGiuliana Gelsomino
Giuliana Gelsomino
MMMichela Matteoli
Michela Matteoli
The regulation of filopodia plays a crucial role during neuronal development and synaptogenesis. Axonal filopodia, which are known to originate presynaptic specializations, are regulated in response to neurotrophic factors. The structural components of filopodia are actin filaments, whose dynamics and organization are controlled by ensembles of actin-binding proteins. How neurotrophic factors regulate these latter proteins remains, however, poorly defined. Here, using a combination of mouse genetic, biochemical, and cell biological assays, we show that genetic removal of Eps8, an actin-binding and regulatory protein enriched in the growth cones and developing processes of neurons, significantly augments the number and density of vasodilator-stimulated phosphoprotein (VASP)-dependent axonal filopodia. The reintroduction of Eps8 wild type (WT), but not an Eps8 capping-defective mutant, into primary hippocampal neurons restored axonal filopodia to WT levels. We further show that the actin barbed-end capping activity of Eps8 is inhibited by brain-derived neurotrophic factor (BDNF) treatment through MAPK-dependent phosphorylation of Eps8 residues S624 and T628. Additionally, an Eps8 mutant, impaired in the MAPK target sites (S624A/T628A), displays increased association to actin-rich structures, is resistant to BDNF-mediated release from microfilaments, and inhibits BDNF-induced filopodia. The opposite is observed for a phosphomimetic Eps8 (S624E/T628E) mutant. Thus, collectively, our data identify Eps8 as a critical capping protein in the regulation of axonal filopodia and delineate a molecular pathway by which BDNF, through MAPK-dependent phosphorylation of Eps8, stimulates axonal filopodia formation, a process with crucial impacts on neuronal development and synapse formation. Neurons communicate with each other via specialized cell–cell junctions called synapses. The proper formation of synapses (“synaptogenesis”) is crucial to the development of the nervous system, but the molecular pathways that regulate this process are not fully understood. External cues, such as brain-derived neurotrophic factor (BDNF), trigger synaptogenesis by promoting the formation of axonal filopodia, thin extensions projecting outward from a growing axon. Filopodia are formed by elongation of actin filaments, a process that is regulated by a complex set of actin-binding proteins. Here, we reveal a novel molecular circuit underlying BDNF-stimulated filopodia formation through the regulated inhibition of actin-capping factor activity. We show that the actin-capping protein Eps8 down-regulates axonal filopodia formation in neurons in the absence of neurotrophic factors. In contrast, in the presence of BDNF, the kinase MAPK becomes activated and phosphorylates Eps8, leading to inhibition of its actin-capping function and stimulation of filopodia formation. Our study, therefore, identifies actin-capping factor inhibition as a critical step in axonal filopodia formation and likely in new synapse formation.

17 May 2013 in The EMBO Journal
Verified
Journal Article
Open access
PDF file
EMElisabetta Menna
Elisabetta Menna
SZStefania Zambetti
Stefania Zambetti
RMRaffaella Morini
Raffaella Morini
ADAndrea Donzelli
Andrea Donzelli
Andrea DisanzaAndrea Disanza
Andrea Disanza
MMMichela Matteoli
Michela Matteoli
Actin‐based remodelling underlies spine structural changes occurring during synaptic plasticity, the process that constantly reshapes the circuitry of the adult brain in response to external stimuli, leading to learning and memory formation. A positive correlation exists between spine shape and synaptic strength and, consistently, abnormalities in spine number and morphology have been described in a number of neurological disorders. In the present study, we demonstrate that the actin‐regulating protein, Eps8, is recruited to the spine head during chemically induced long‐term potentiation in culture and that inhibition of its actin‐capping activity impairs spine enlargement and plasticity. Accordingly, mice lacking Eps8 display immature spines, which are unable to undergo potentiation, and are impaired in cognitive functions. Additionally, we found that reduction in the levels of Eps8 occurs in brains of patients affected by autism compared to controls. Our data reveal the key role of Eps8 actin‐capping activity in spine morphogenesis and plasticity and indicate that reductions in actin‐capping proteins may characterize forms of intellectual disabilities associated with spine defects.